



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/885,188	06/21/2001	Chris Somerville	PW 280903/20263	7811

9629 7590 10/03/2002
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004

EXAMINER
MCELWAIN, ELIZABETH F

ART UNIT	PAPER NUMBER
1638	11

DATE MAILED: 10/03/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/885,188	SOMERVILLE ET AL.
	Examiner	Art Unit
	Elizabeth McElwain	1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 June 2001.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-21 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-21 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

Claims 1-21 are pending.

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-3, 6-10, 12 and 14-17, drawn to a nucleic acid sequence encoding SEQ ID NO: 4, a chimeric gene and plants comprising said sequence, and a method of 5 modifying a plant by transforming the plant with said sequence, classified in Class 800, subclass 281, for example.

II. Claims 4, 5, 11, 12, 18 and 19, to the extent that the claims are drawn to a nucleic acid sequence encoding SEQ ID NO: 1, a chimeric gene and plants comprising said sequence, and a method of modifying a plant by transforming the plant with said sequence, 10 classified in Class 800, subclass 281, for example.

III. Claims 4, 5, 11, 12, 18 and 19, drawn to a nucleic acid sequence encoding SEQ ID NO: 2, a chimeric gene and plants comprising said sequence, and a method of modifying a plant by transforming the plant with said sequence, classified in Class 800, subclass 281, for example.

IV. Claims 4, 5, 11, 12, 18 and 19, drawn to a nucleic acid sequence encoding SEQ ID NO: 3, a chimeric gene and plants comprising said sequence, and a method of modifying a plant by transforming the plant with said sequence, classified in Class 800, subclass 281, for example.

V. Claim 13, drawn to oil, classified in Class 426, subclass 601, for example.

VI. Claim 20, drawn to a triglyceride oil, classified in Class 436, subclass 71, for example.

VII. Claim 21, drawn a method of isolating a nucleic acid fragment, classified in Class 435, subclass 6, for example.

5

The inventions are distinct, each from the other because of the following reasons:

Applicants are reminded that nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 10 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Inventions I-IV are each distinct products and processes of use. Each is drawn to a distinct nucleic acid coding for a distinct enzymes, wherein each differs chemically and 15 structurally, and the method of using one does not require the other and the plant transformed with one does not require the other. In addition, the products of Groups V and VI are distinct chemical compositions one from the other and also differ from the products of Groups I-IV, which each differ chemically and structurally, and one is not required by the others, wherein the oils and triglycerides of Groups V and VI can be made by another method than by using 20 the plants of Groups I-IV, such as by chemical synthesis. Furthermore, the method of Group VII, is not required by any of the methods or products of Groups I-VI, and the nucleic acids of

Groups I-IV can be used in a method other than for isolating a nucleic, such as for expression of a polypeptide in a plant, for example. Therefore, the inventions of Groups I-VII are capable of being separately made, independently used and the patentability one would not render either of the other obvious or unpatentable.

5 Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown for their different classification and the requirement for additional areas of search restriction for examination purposes as indicated is proper.

10 Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed
15 petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

20 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (703) 308-1794. The examiner can normally be reached on Monday through Friday from 8:00 AM to 4:30 PM.

25 If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone number for this Group is (703) 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).


Serial No. 09/885,188
Art Unit 1638

-5-

Any inquiry of a general nature or relating to the status of this application should be directed to the legal analyst, Gwendolyn Payne, whose telephone number is (703) 305-2475, or to the Group receptionist whose telephone number is (703) 308-0196.

5

Elizabeth F. McElwain, Ph.D.
October 1, 2002


ELIZABETH F. McELWAIN
PRIMARY EXAMINER
GROUP 1600*